Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Zhu-Chen Zhou *Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.ORCID 0000-0001-5096-3903
Meng-Ting Liu *Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.
Yi-Jia Fangma *Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.ORCID 0000-0002-5101-6008
Bing-Jie Wan *Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.
Jing ZhouZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.ORCID 0000-0002-8378-4431
Xiao-Lan ZhangZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.
Yu-Ting YanZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.
Shu-Hui DengZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.
Yan ZhangZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.ORCID 0009-0003-9479-9270
Yuan-Jie ZhangZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.
Wen-Lu LiZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.
Zhong ChenZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.ORCID 0000-0003-4755-9357
Yan-Rong ZhengZhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University Hangzhou China.ORCID 0000-0001-6253-9835
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundInflammasome hyperactivation drives neuroinflammation following cerebral ischemia, yet pharmacological strategies inducing their selective clearance remain largely unexplored. Selective autophagy holds particular promise as a therapeutic strategy by eliminating detrimental substrates while avoiding the side effects of excessive autophagy. However, few compounds are currently available to achieve this selective regulation.
methodsTransient middle cerebral artery occlusion was used to screen the active compounds from
resultsPeiminine demonstrates robust neuroprotection after cerebral ischemia. RNA sequencing and immunoblotting analyses revealed that peiminine markedly suppresses postischemic inflammation. Correspondingly, peiminine exerts its neuroprotective effect primarily through actions on microglia but not astrocytes, indicated by neuron-glia cocultures and transgenic mice models with targeted cell-type depletion. Biolayer interferometry and molecular dynamics simulations indicated that peiminine selectively binds to AIM2, showing no interaction with NLRP1 (NLR family pyrin domain containing 1) and approximately 100-fold higher affinity compared with NLRP3. Notably, peiminine specifically activates the selective autophagic clearance of AIM2 inflammasomes within microglia without increasing overall autophagic flux or affecting other inflammasomes. Selective blockage of autophagy in microglia abolished the neuroprotective effect of peiminine.
conclusionsPeiminine exhibited robust neuroprotection against cerebral ischemia by selectively promoting the autophagic clearance of AIM2 inflammasomes to mitigate neuroinflammation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Peiminine-Induced Selective Autophagy of AIM2 Inflammasomes Rescues Cerebral Ischemic Injury. · full record | OpenQuestion